Fibroproliferative genes are preferentially expressed in central centrifugal cicatricial alopecia - 15/10/18
Abstract |
Background |
Central centrifugal cicatricial alopecia (CCCA) is a primary cicatricial alopecia that most commonly affects women of African descent. Like CCCA, fibroproliferative disorders (FPDs) such as keloids, atherosclerosis, and fibroids are characterized by low-grade inflammation and irritation, resulting in end-stage fibrosis.
Objective |
We sought to determine whether fibroproliferative genes were up-regulated in patients with CCCA.
Methods |
A total of 5 patients with biopsy-proven CCCA were recruited for this study. Two scalp biopsy specimens were obtained from each patient; 1 from CCCA-affected vertex scalp and 1 from the unaffected occipital scalp. Microarray analysis was performed to determine the differential gene expression patterns.
Results |
There was an upregulation of genes implicated in FPDs in patients with CCCA. Specifically, we noted increased expression of platelet derived growth factor gene (PDGF), collagen I gene (COL I), collagen III gene (COL III), matrix metallopeptidase 1 gene (MMP1), matrix metallopeptidase 2 gene (MMP2), matrix metallopeptidase 7 gene (MMP7), and matrix metallopeptidase 9 gene (MMP9) in affected scalp compared with in unaffected scalp. Significant overlap in the canonic pathways was noted between patients with CCCA and patients with both atherosclerosis and hepatic fibrosis (P < .001).
Limitations |
Small sample size and the use of whole skin tissue for analysis.
Conclusion |
We have identified the upregulation of critical genes implicated in FPDs in the gene expression profile of patients with CCCA. These findings may help identify future therapeutic targets for this otherwise difficult-to-treat condition.
Le texte complet de cet article est disponible en PDF.Key words : alopecia, central centrifugal cicatricial alopecia, cicatricial alopecia, fibroproliferative disorders, fibrosis, therapy
Abbreviations used : CCCA, ECM, FPD, IPA, IPF, SD, UF
Plan
Funding sources: Supported by the Dr Stanford Lamberg Research Award. Ms Dina is a participant of the Vanderbilt Medical Scholars Program and is partially funded by a National Institutes of Health Clinical and Translational Science Awards grant (UL1 RR 024975). Dr Garza was supported by grants R01AR064297 and AR068280 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, which is part of the National Institutes of Health. |
|
Conflicts of interest: None disclosed. |
|
Presented at the International Investigative Dermatology 2018 Meeting in Orlando, FL, May 16-19, 2018. |
Vol 79 - N° 5
P. 904 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?